1. Home
  2. TBBK vs EVO Comparison

TBBK vs EVO Comparison

Compare TBBK & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBBK
  • EVO
  • Stock Information
  • Founded
  • TBBK 1999
  • EVO 1993
  • Country
  • TBBK United States
  • EVO Germany
  • Employees
  • TBBK N/A
  • EVO N/A
  • Industry
  • TBBK Major Banks
  • EVO Biotechnology: Pharmaceutical Preparations
  • Sector
  • TBBK Finance
  • EVO Health Care
  • Exchange
  • TBBK Nasdaq
  • EVO Nasdaq
  • Market Cap
  • TBBK 2.4B
  • EVO 1.5B
  • IPO Year
  • TBBK 2004
  • EVO 2021
  • Fundamental
  • Price
  • TBBK $57.98
  • EVO $4.20
  • Analyst Decision
  • TBBK Buy
  • EVO Buy
  • Analyst Count
  • TBBK 3
  • EVO 2
  • Target Price
  • TBBK $65.33
  • EVO $5.90
  • AVG Volume (30 Days)
  • TBBK 520.5K
  • EVO 112.1K
  • Earning Date
  • TBBK 07-24-2025
  • EVO 08-13-2025
  • Dividend Yield
  • TBBK N/A
  • EVO N/A
  • EPS Growth
  • TBBK 20.50
  • EVO N/A
  • EPS
  • TBBK 4.42
  • EVO N/A
  • Revenue
  • TBBK $502,282,000.00
  • EVO $851,944,444.00
  • Revenue This Year
  • TBBK N/A
  • EVO $10.08
  • Revenue Next Year
  • TBBK $6.71
  • EVO $10.99
  • P/E Ratio
  • TBBK $12.90
  • EVO N/A
  • Revenue Growth
  • TBBK 10.02
  • EVO 1.50
  • 52 Week Low
  • TBBK $37.49
  • EVO $2.84
  • 52 Week High
  • TBBK $65.84
  • EVO $5.64
  • Technical
  • Relative Strength Index (RSI)
  • TBBK 62.12
  • EVO 52.85
  • Support Level
  • TBBK $54.12
  • EVO $4.15
  • Resistance Level
  • TBBK $58.39
  • EVO $4.33
  • Average True Range (ATR)
  • TBBK 1.57
  • EVO 0.11
  • MACD
  • TBBK 0.55
  • EVO 0.01
  • Stochastic Oscillator
  • TBBK 75.53
  • EVO 61.97

About TBBK The Bancorp Inc

The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, specialty finance (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Specialty finance includes REBL (real estate bridge lending) comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: